American Regent secures rare PI win in Hatch-Waxman dispute

Pharma giant wins preliminary injunction ‘in public interest’ regarding a generic of its Selenious Acid Injection | Judge finds infringement by pharma company Eugia of two Orange Book patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Bayer, Orion take on Indian generic over $117bn drug

8 July 2025 German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer blockbuster | Suit follows leadership shakeup at Bayer.

Americas

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

17 June 2025 Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.

Europe

‘Always new twists’: Bayer legal team on defending a $4bn drug

31 March 2025 With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster blood thinner from generics. Marisa Woutersen finds Bayer’s outside litigation counsel ready for anything.

More on this story

Americas

Bayer, Orion take on Indian generic over $117bn drug

8 July 2025 German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer blockbuster | Suit follows leadership shakeup at Bayer.

Americas

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

Europe

‘Always new twists’: Bayer legal team on defending a $4bn drug

More on this story

Americas

Bayer, Orion take on Indian generic over $117bn drug

8 July 2025 German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer blockbuster | Suit follows leadership shakeup at Bayer.

Americas

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

Europe

‘Always new twists’: Bayer legal team on defending a $4bn drug